Items where authors include "Bonnelye, E."

Article

Clezardin, P. orcid.org/0000-0003-0149-4463, Coleman, R., Puppo, M. et al. (5 more authors) (2021) Bone metastasis : mechanisms, therapies and biomarkers. Physiological Reviews, 101 (3). pp. 797-855. ISSN 0031-9333

Pantano, F., Croset, M., Driouch, K. et al. (15 more authors) (2021) Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. Oncogene, 40 (7). pp. 1284-1299. ISSN 0950-9232

Bouchet, M., Lainé, A., Boyault, C. et al. (13 more authors) (2020) ERRα expression in bone metastases leads to an exacerbated anti-tumor immune response. Cancer Research, 80 (13). pp. 2914-2926. ISSN 0008-5472

Vargas, G., Bouchet, M., Bouazza, L. et al. (22 more authors) (2019) ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. Oncogene, 38 (7). pp. 950-964. ISSN 0950-9232

Gineyts, E., Bonnet, N., Bertholon, C. et al. (17 more authors) (2018) The C-terminal intact forms of periostin (iPTN) are surrogate markers for osteolytic lesions in experimental breast cancer bone metastasis. Calcified Tissue International, 103 (5). pp. 567-580. ISSN 0171-967X

Croset, M., Pantano, F., Kan, C.W.S. et al. (10 more authors) (2018) miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis–associated genes. Cancer Research, 78 (18). pp. 5259-5273. ISSN 0008-5472

Reynaud, C., Ferreras, L., Di Mauro, P. et al. (9 more authors) (2017) Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Cancer Research, 77 (2). pp. 268-278. ISSN 0008-5472

Fradet, A., Bouchet, M., Delliaux, C. et al. (17 more authors) (2016) Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone. Oncotarget, 7 (47). pp. 77071-77086.

Fradet, A., Sorel, H., Depalle, B. et al. (8 more authors) (2013) A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. PLoS One, 8 (9). e75092. ISSN 1932-6203